SummaryHigh-risk neuroblastoma remains one of the deadliest childhood cancers. Identification of metabolic pathways that drive or maintain high-risk neuroblastoma may open new avenues of therapeutic interventions. Here, we report the isolation and propagation of neuroblastoma sphere-forming cells with self-renewal and differentiation potential from tumors of the TH-MYCN mouse, an animal model of high-risk neuroblastoma with MYCN amplification. Transcriptional profiling reveals that mouse neuroblastoma sphere-forming cells acquire a metabolic program characterized by transcriptional activation of the cholesterol and serine-glycine synthesis pathways, primarily as a result of increased expression of sterol regulatory element binding factors a...
Neuroblastoma is the first neurogenic-extracranial solid cancer occurring in infancy and childhood. ...
grantor: University of TorontoSeveral biological and clinical features of neuroblastoma su...
High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, th...
High-risk neuroblastoma remains one of the deadliest childhood cancers. Identification of metabolic ...
SummaryHigh-risk neuroblastoma remains one of the deadliest childhood cancers. Identification of met...
Neuroblastoma is a pediatric cancer responsible for approximately 15% of all childhood cancer deaths...
Neuroblastoma, the most common extracranial solid malignancy among children, originates from undiffe...
Many metabolic pathways, including lipid metabolism, are rewired in tumors to support energy and bio...
Nearly half of patients with neuroblastoma present with high-risk disease, which often has poor outc...
Neuroblastoma is the most common and aggressive extracranial solid tumor during childhood. MYCN-ampl...
The MYC genes are the most frequently activated oncogenes in human tumors and are hence attractive t...
Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional trea...
High risk neuroblastoma (NB) is responsible for nearly 15% of all cancer related deaths in the pedia...
MYCN is a transcription factor that is aberrantly expressed in many tumor types and is often correla...
Neuroblastoma (NB) is a heterogeneous pediatric tumor. To better understand the biological pathways ...
Neuroblastoma is the first neurogenic-extracranial solid cancer occurring in infancy and childhood. ...
grantor: University of TorontoSeveral biological and clinical features of neuroblastoma su...
High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, th...
High-risk neuroblastoma remains one of the deadliest childhood cancers. Identification of metabolic ...
SummaryHigh-risk neuroblastoma remains one of the deadliest childhood cancers. Identification of met...
Neuroblastoma is a pediatric cancer responsible for approximately 15% of all childhood cancer deaths...
Neuroblastoma, the most common extracranial solid malignancy among children, originates from undiffe...
Many metabolic pathways, including lipid metabolism, are rewired in tumors to support energy and bio...
Nearly half of patients with neuroblastoma present with high-risk disease, which often has poor outc...
Neuroblastoma is the most common and aggressive extracranial solid tumor during childhood. MYCN-ampl...
The MYC genes are the most frequently activated oncogenes in human tumors and are hence attractive t...
Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional trea...
High risk neuroblastoma (NB) is responsible for nearly 15% of all cancer related deaths in the pedia...
MYCN is a transcription factor that is aberrantly expressed in many tumor types and is often correla...
Neuroblastoma (NB) is a heterogeneous pediatric tumor. To better understand the biological pathways ...
Neuroblastoma is the first neurogenic-extracranial solid cancer occurring in infancy and childhood. ...
grantor: University of TorontoSeveral biological and clinical features of neuroblastoma su...
High-risk neuroblastomas show a paucity of recurrent somatic mutations at diagnosis. As a result, th...